Abstract:ABSTRACT Our review summarizes and compares the temporal development (eras) of antifungal drug discovery as well as antibacterial ventures. The innovation gap that occurred in antibacterial discovery from 1960 to 2000 was likely due to tailoring of existing compounds to have better activity than predecessors. Antifungal discovery also faced innovation gaps. The semi-synthetic antibiotic era was followed closely by the resistance era and the heightened need for new compounds and targets. With the immense contribution of comparative genomics, antifungal targets became part of the discovery focus. These targets by definition are absolutely required to be fungal- or even lineage (clade) specific. Importantly, targets need to be essential for growth and/or have important roles in disease and pathogenesis. Two types of antifungals are discussed that are mostly in the FDA phase I–III clinical trials. New antifungals are either modified to increase bioavailability and stability for instance, or are new compounds that inhibit new targets. One of the important developments in incentivizing new antifungal discovery has been the prolific number of publications of global and country-specific incidence. International efforts that champion global antimicrobial drug discovery are discussed. Still, interventions are needed. The current pipeline of antifungals and alternatives to antifungals are discussed including vaccines.

New Lead Structures in Antifungal Drug Discovery

[Recent Advances in the Study of Antifungal Lead Compounds with New Chemical Scaffolds].

Lipopeptid Antifungals and Their Structural Modifications

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Strategies in the Discovery of Novel Antifungal Scaffolds

Discovery of Highly Potent Antifungal Triazoles by Structure-Based Lead Fusion

Innovations in Antifungal Drug Discovery among Cell Envelope Synthesis Enzymes through Structural Insights

Design, Synthesis and Antifungal Activity of Carbazole Derivatives

Design and Synthesis of Antifungal Benzoheterocyclic Derivatives by Scaffold Hopping

New azoles with potent antifungal activity: design, synthesis and molecular docking.

Structure-based design, synthesis, and antifungal activity of new triazole derivatives.

Structure-based Virtual Screening and ADME/T-based Prediction Analysis for the Discovery of Novel Antifungal CYP51 Inhibitors.

Antifungal Drug Discovery: the Process and Outcomes

Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall

Discovery of highly potent triazoleantifungal agents with piperidine-oxadiazole side chains

Searching for Conjugates as New Structures for Antifungal Therapies

Design, Synthesis, Evaluation and Optimization of Novel Azole Analogues As Potent Antifungal Agents

Progress on antifungal drug targets and inhibitors

The Antifungal Pipeline: the Need is Established. Are There New Compounds?

Discovery of Biphenyl Imidazole Derivatives As Potent Antifungal Agents: Design, Synthesis, and Structure-Activity Relationship Studies.

Discovery of Simplified Sampangine Derivatives As Novel Fungal Biofilm Inhibitors.